Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Do topical interventions improve outcomes in addition to cryosurgery for actinic keratoses compared with cryosurgery alone?
Bottom line
Based on a review of low-quality evidence, adding a topical intervention after cryosurgery for actinic keratosis improves the likelihood of complete clearance from 46% to 79% (number needed to treat [NNT] = 3). In the absence of better evidence, 5-fluorouracil (5-FU) and diclofenac may be preferable to ingenol mebutate based on cost. 1a-
Reference
Study design: Meta-analysis (randomized controlled trials)
Funding: Foundation
Setting: Various (meta-analysis)
Synopsis
The authors of this well-conducted meta-analysis screened 1758 studies and ultimately included only 9 of them. Limitations include the often poor descriptions of the studies, with unclear accounts of randomization or allocation concealment, and the failure to mask the participants in 5 trials and the outcome assessors in 2 trials. The topical interventions applied after cryosurgery for actinic keratosis included imiquimod in 4 studies, ingenol mebutate in 2 studies, diclofenac 3% in 2.5% hyaluronic acid in 1 study, 5-fluorouracil 0.5% cream in 1 study, and photodynamic therapy with aminolevulinic acid (ALA-PDT) in 1 study. The overall likelihood of complete lesion clearance when combining all 9 studies was greater with the addition of topical therapy (relative risk [RR] 1.74; 95% CI 1.25 - 2.43). Applied to a base rate of complete lesion clearance of 46% with cryosurgery alone, the addition of a topical intervention would increase the rate to 79%. A similar pattern was seen for partial clearance in 3 studies with 421 patients (RR 1.64; 0.88 - 3.03). There was no difference in withdrawals, indicating good tolerability. However, there was substantial heterogeneity between studies (I2 = 73%). Individual studies of diclofenac, 5-FU, and ingenol mebutate showed significant benefit consistent with the overall effect, while imiquimod and ALA-PDT did not, but sample sizes for most studies were small
Reviewer
Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA